Head of North American Operations Optibrium Limited, England, United Kingdom
New advances in data science and AI bring valuable insights and cost-savings that drive discovery projects. We will explore the challenges and drivers impacting the adoption of AI in discovery organisations including pharma, biotech, academia and not-for-profit. We will illustrate these using case studies on the application of Optibrium’s Cerella™ platform for deep-learning imputation with collaborators in drug discovery and other chemistry optimisation fields. Common themes highlight bottlenecks and gaps in current discovery approaches and valuable applications of AI that address them.
